• Partnered with client’s internal Market Planning function to design and execute clinical reports perceptions/reactions market research. Provided input on project objectives, defined structure project approach, contributed to analysis design, review and analysis of outputs, managed 3rd party vendor.
• Partnered with client’s internal Market Planning function to design and execute Awareness, Trial and Usage Market Research (ATU). This entailed facilitating discussions and recommendation for 3rd party vendor; working closely with vendor and client’s team on survey development and design; providing guidance to facilitate internal alignment on key metrics for tracking, to analyze fielding of the study, to define analysis for the deliverable and provide feedback on the final report.

• Managed Market Intelligence team, group of 4 high performing employees, responsible for Market Research, Competitive Intelligence and Quantitative analytics across all Business Units (Sleep, Oncology, and Psych)
• Developed vision and strategy for the team to provide “best-in-class” analyses for decision-making at Jazz
• Established Quantitative Analytics sub-team to provide more quantitative insights and data driven decisions across the Brands: a more disciplined and objective approach to ROI/promotional effectiveness as well as consistent frameworks/KPIs across BUs
• Developed high-value partnerships with Sales Analytics, Forecasting, Health Systems and Business Intelligence in order to implement a more integrated and comprehensive “brand focus” approach to data analysis & insights
• Supported and helped implement development of individual employees (educational seminars, sales ride-alongs, career development plans, etc)

• Led commercial assessments for diligence products across multiple therapeutic areas (>10 assessments)
• Determined commercial value and strategic fit with Jazz’s unique culture
• Conducted primary and secondary analytics: qualitative/quantitative market research, competitive intelligence, and forecasting scenario analyses
• Mobilized cross-functional teams to align on key forecast inputs and analyses: Corporate Development, Medical Affairs, Regulatory, external consultants, etc
• Presented commercial assessments with Go/No Go recommendations to Senior Management team and when appropriate to the full Executive Committee
• Led commercial assessment in Acute Myeloid Leukemia (AML) and was integral part of the Deal Team for Celator acquisition
• Instrumental in laying the groundwork for this acquisition across internal stakeholders and Sr Management
• Resulted in acquisition of Celator in May 2016 for $1.5Bill. Vyxeos got approved in AML in A

• Acted as a primary competitive intelligence liaison with Janssen Biotech Inc (JBI) for ibrutinib
• Developed and managed competitive intelligence (CI) structure and process for ibrutinib in mantle (MCL) and chronic lymphocytic lymphomas (CLL) with the following deliverables: monthly competitive landscape reports, weekly CI updates, and deep dive analyses for key individual competitors. These were shared across both organizations including Sr Management
• Led primary qualitative market research study for ibrutinib in Waldenstrom indication and presented findings to the commercial team
• Developed MCL situation analysis which included disease and competitive landscape overviews in support of brand strategies and tactics for successful ibrutinib launch
• Evaluated different secondary data resources for competitive intelligence analytics

• Led US primary market research and secondary research for Nexavar approved indications -HCC and RCC- and lifecycle indications (NCSL, breast). Collaborated with Bayer on Regorafenib market research for lifecycle indications (Colorectal, GIST).
• Developed global (US, EU, Japan) competitive intelligence framework and process for KI franchise (Nexavar/Regorafenib) across all indications.